Encouraging a Pull incentive in the US: Now is the time for a note from you or your company

Dear All:

You are doubtless now familiar with all the reasons why we need pull incentives for AMR-related products (as background, see this blog). We don’t yet have anything beyond the US GAIN act and it alone will not suffice.

In the US, there are discussions this week in the House of Representatives on reauthorizing PAHPA, the Pandemic and All-Hazards Preparedness Reauthorization Act. Language about market entry rewards (specifically, Transferable Conveyance Awards, TCAs, the new language for transferable exclusivity vouchers) has been in and out of the revised Act, but is currently NOT included.

Although TCAs are not perfect, they appear to be the best way for the US to implement something that approximates the idea of a Market Entry Reward (MER) that was proposed by DRIVE-AB for AMR-related products. If implemented with suitable care, it seems obvious that you could use a TCA to provide the type of delinked payments that are at the heart of the MER idea. If you agree with this viewpoint, today would be a really good day for you (or your company’s CEO) to send a note (separately) to any or all of the the staffers working for these representatives:

  • Rep. Doris Matsui (D-CA): megan.herber@mail.house.gov
  • Rep. Anna Eshoo (D-CA): rachel.fybel@mail.house.gov
  • Rep. Tony Cardenas (D-CA): Jacqueline.Usyk@mail.house.gov
  • Rep. Diane DeGette (D-CO): michelle.greenhalgh@mail.house.gov
  • Rep. Brett Guthrie (R-KY): sophie.trainor@mail.house.gov
  • Rep .Leonard Lance (R-NJ): Robert.Butora@mail.house.gov
  • Rep. Chris Collins (R-NY): charlotte.pineda@mail.house.gov
  • Rep. Marsha Blackburn (R-TN): meghan.stringer@mail.house.gov

David Shlaes has posted a good set of talking points on his Perfect Storm blog. You could use those ideas as well as the materials cited above to help you write a brief message regarding your work in this area, your geography (if relevant to the given Representative), your concern about the negative economics of work in this area, and the value that a Pull incentive such as the TCA would have for you or your company would be appropriate.  

Separately, see the Upcoming Meetings list … a detailed summary from last summer’s NIAID PK-PD workshop has now been published.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

Upcoming meetings of interest to the AMR community:

Share

Conflict-Borne XDR Superbugs: It’s Time for the PASTEUR Act!

Dear All: The recent publication of an exceptionally good plain-language summary of the AMR problem in Rolling Stone (yes, you read that correctly!) prompts today’s 3-part journey into the way(s) that war contributes to the threat of resistant superbugs. We’ve summarized the story in outline form — please explore the references for further details. And

ENABLE-2 funding now includes Hit Identification & Validation

23 July 2024 addenda x 2:  Mark Blaskovich let me know that the CO-ADD project is still offering a free in vitro screening service. See https://www.co-add.org/ to submit compounds for free testing vs 5 bacteria and 2 fungi; see https://db.co-add.org/ for structures and screening data on >100K compounds. The GHIT Fund has announced its 21st Request for Proposals for its Hit-to-Lead Platform to

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

Scroll to Top